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Aim of the study: We developed an experimental rat model to explore the possibility of enhancing the healing of
critical-size bone defects. The aim of this study was to demonstrate the feasibility of this concept by achieving high
local BMP-2 expression via a transduced muscle flap that would facilitate bony union while minimizing systemic
sequelae.
Methods: The transduction potential of the adenoviral vector encoding for BMP-2 was tested in different cell
lines in vitro. In vivo experiments consisted of harvesting a pedicled quadriceps femoris muscle flap with subsequent
creation of a critical-size defect in the left femur in Sprague-Dawley rats. Next, the pedicled muscle flap was perfused
with high titers of Ad.BMP-2 and Ad.GFP virus, respectively. Twelve animals were divided into three groups comparing
the effects of Ad.BMP-2 transduction to Ad.GFP and placebo. Bone healing was monitored radiologically with subsequent
histological analysis post-mortem.
Results: The feasibility of this concept was demonstrated by successful transduction in vitro and in vivo as evidenced by a
marked increase of BMP-2 expression. The three examined groups only showed minor difference regarding bone
regeneration; however, one complete bridging of the defect was observed in the Ad.BMP-2 group. No evidence
of systemic viral contamination was noted.
Conclusions: A marked increase of local BMP-2 expression (without untoward systemic sequelae) was detected.
However, bone healing was not found to be significantly enhanced, possibly due to the small sample size of the
study.
Keywords: Bone regeneration, Gene therapy, Reconstructive microsurgery, Bone morphogenetic protein, BMP-2,
Regenerative medicine, Translational medicine, Tissue engineeringIntroduction
A critical-size bone defect is, by definition, unable
to regain bony union without intervention. The gold
standard treatment of such defects is transplantation of
autologous bone [1]. However, donor-site morbidity and
limited availability represent drawbacks of this approach.
In contrast, allogenic bone grafts are readily available;* Correspondence: florian.lampert@uniklinik-freiburg.de
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unless otherwise stated.however, they have a considerably lower osteoinductive
potential and bear the risk of transplant rejection as well
as transmission of infectious diseases [2]. Bone regener-
ation through topical application of synthetic growth
factors has already been demonstrated. In particular, ad-
ministration of BMP-2 has been used with considerable
success in orthopedic surgery and neurosurgery [3-6].
Limitations of this approach, however, include 1) high
cost and 2) need for repeated applications secondary to
the short half-life of the protein. Other experimental
therapies include the development of injectable biologicall. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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mal stem cells to BMP-2 ex vivo, thus, inducing their
osteoblastic differentiation [7,8]. Transduction of target
cells with a replication-deficient adenovirus, designed to
carry cDNA encoding for BMP-2, represents a novel ap-
proach for local delivery of BMP-2 to the region of inter-
est. Previous studies have shown significant improvement
of bone regeneration after local application of BMP-2 car-
rying adenoviruses to the bone defect in a rat model
[9-11]. Injecting very high virus titers directly into the
bone defect, however, can lead to systemic spreading of
the virus, with a resultant negative impact on other or-
gans, along with initiation of potentially severe or even le-
thal immunological reactions [12]. In order to minimize
the risk of systemic contamination of the replication-
deficient adenovirus used in the present study, a pedicled
quadriceps muscle flap was harvested and selectively in-
fused with the virus. The concept of using genetically al-
tered soft tissue flaps as biologic pumps has been
demonstrated by Liu et al. and Michaels et al. in a rat
model [13-15]. The present study represents the first at-
tempt of assessing whether muscle flaps can be altered
genetically so as to not only provide soft tissue coverage
but also enhance osseous healing by local production of
growth factors, as muscle tissue is known to possess an
ample quantity of mesenchymal stem cells capable of
osteoblastic differentiation [8]. Furthermore, BMP-2 has
an angiogenetic potential, which could aid in facilitating
the healing process [16].
Materials and methods
Viral vector
Replication-deficient viruses were used in the present
study, i.e., Ad.BMP-2 and Ad.GFP vector (courtesy
of Dr. O. Betz, Munich). These vectors represent
two subtypes of a replication-deficient E1/E3-deleted
adenovirus type 5 vector driven by a cytomegalovirus
promoter. Human BMP-2 cDNA and GFP (green fluor-
escent protein) cDNA were cloned into the E1 domain,
respectively. The virus was amplified in a HEK 293 cell
line and titered using HEK 293 standard plaque assay.
The concentration of infective particles is indicated as
plaque-forming units per milliliter (PFU/ml) and set in
relation to the number of target cells as MOI (multipli-
city of infection). Adenoviral vector efficiency was first
assessed in vitro in the following human and rat cell
types:
– MSC - human mesenchymal stem cells (obtained by
bone marrow biopsy at the University of Freiburg
Medical Center)
– Cal-72 human osteosarcoma cells (ACC 439
Deutsche Sammlung von Mikroorganismen und
Zellkulturen Braunschweig, Germany)– SaOs-2 human osteosarcoma cells (ACC 243
Deutsche Sammlung von Mikroorganismen und
Zellkulturen Braunschweig, Germany)
– HUVEC - human umbilical vein endothelial cells
(Promocell, Cat. No. C-12250, Heidelberg,
Germany)
– Sprague Dawley rat myocyte cell culture isolated
from the quadriceps muscle
The cultured cells were incubated on six-well plates at
37°C/5% CO2 until confluence was reached, then 1 ml of
virus suspension (Ad.GFP or Ad.BMP-2) was added to
the medium. Five days after transduction, the efficiency
of transduction was evaluated. BMP-2 levels in the
culture medium were measured with a human BMP-2-
specific ELISA assay (DBP 200). The cultures transfected
with GFP-2 were examined microscopically for UV
fluorescence.
Animals
Adult male Sprague Dawley rats weighing 400–450 g
(Charles River, Sulzfeld, Germany) were used for in vivo
experiments. All animals were kept in an approved ani-
mal care facility with 12-h light/dark cycles and were
allowed food and water ad libitum and unrestricted ac-
tivity after surgery. All animal studies were approved by
the ethical review board of Baden-Württemberg (G 07/
33) and conducted in compliance with the guidelines
specified in German legislation concerning animal ex-
periments (Tierschutzgesetz, §§ 7 to 9).
Animals were divided into three groups:
– Group 1: BMP group (n = 4): muscle flap infused
with 1-ml Ad.BMP-2 suspension (8 × 109 PFU/ml),
– Group 2: GFP group (n = 4): muscle flap infused
with 1-ml Ad.GFP suspension (6 × 109 PFU/ml),
– Group 3: control group (n = 4): muscle flap infused
with 1 ml of sterile normal saline.
Surgical procedure
Surgery was performed under general anesthesia using
isoflurane (Forene®, Abbott, Switzerland) at a flow rate
of 1.5 l/min. The left lower extremity was clipped
and prepped using PVP-iodine solution (Beta-Isodona,
Mundipharma, Limburg/Lahn, Germany). A 3-cm skin
incision was made on the medial aspect of the left thigh
with subsequent dissection through the subcutaneous
tissue until the quadriceps muscle was visualized. The
muscle was carefully harvested and left attached only
via its pedicle. All vascular dissections were performed
under the microscope. Next, blood flow was inter-
rupted by clamping the femoral vessels distal to the
iliac ligament. The femoral artery and vein were then
transected distal to the knee joint and a blunt 0.2-mm
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mm microsurgical vascular clamp (Roboz Surgical In-
strument Co., Inc. RS-6470) was placed on the vein.
Then, 1 ml of virus solution containing 8 × 109 plaque-
forming units (BMP group) or 6 × 109 plaque-forming
units (GFP group) was injected into the artery (Figure 1),
followed by an incubation period of 1 h. Controls were
treated by injecting 1 ml of sterile normal saline. The
femur defect was created during the incubation period. A
micro-plate (KLSMartin, Tuttlingen, Germany) was se-
cured to the femur using four screws [17]. After fixation, a
5-mm defect (i.e., critical-size defect) [10] was created in
the middle of the femoral shaft using a burr. After the in-
cubation period, the venous clamp was removed and the
flap was flushed with sterile normal saline solution (0.9%)
via the femoral artery to remove any non-incorporated
viruses. The surgical site was irrigated with PVP-iodine
solution and saline to minimize local viral contamination
[18]. After insetting the flap into its original location using
5-0 Vicryl® (Ethicon, Germany), skin closure was per-
formed with Prolene® 4-0 (Ethicon, Germany). All animals
were given prophylactic antibiotics (Borgal® Sulfadoxinum
200 mg, Trimethoprimum 40 mg, 15 mg/kg). Tamgesic®
(15 μg) was administered subcutaneously for pain control
for 5 days postoperatively.
To directly assess the transduction efficiency in vivo,
1 ml Ad.BMP or Ad.GFP virus solution was intraopera-
tively injected in multiple layers into the quadriceps
muscles of three (2× Ad. BMP, 1× Ad.GFP) additional ani-
mals. Transduction efficacy was examined by quantitativeFigure 1 Surgical site. The image demonstrates the elevated
quadriceps muscle flap only attached by its pedicle with the Pravaz
cannula in the afferent artery. The efferent vein is clamped and the
microplate is displayed bridging the femoral critical-size defect. Via
the Pravaz cannula, 1.0 ml of virus solution (8 × 109 plaque-forming
units (BMP group) or 6 × 109 plaque-forming units (GFP group)) were
injected (incubation time 1 h). A micro-plate (KLSMartin, Tuttlingen,
Germany) secures the femur after performing a critical-size defect
(5 mm) in the middle of the femoral shaft.real-time RT-PCR and UV fluorescence, respectively
(Figure 2).BMP-2 ELISA
We used a BMP-2 ELISA kit (R&D Systems, DBP-200
Quantine) to quantify BMP-2 expression in both in vitro
and in vivo experiments analyzing cell culture superna-
tants and tissue sample lysates, respectively. The samples
were normalized to equal protein quantities, either 100
or 300 μg in different experiments, using a BCA protein
Assay Reagent Kit® (Pierce, Thermo Scientific) and added
to each well of the ELISA kit. Absorbance was measured
at 450 nm and correlated to a standard curve obtained
by measuring pre-equilibrated standard samples. The
mean minimum detectable dose was 11 pg/ml. All test
samples were examined in duplicates or triplicates.Quantitative real-time RT-PCR
TaqMan RT-PCR was carried out as previously described
[19]. Total RNA was isolated from tissue samples using
the TRIzol method [20]. Total RNA (0.5 μg) was treated
with 3 units of deoxyribonuclease I (DNase I, Invitrogen,
Karlsruhe, Germany) to digest genomic DNA contamin-
ation. Random-primed cDNA synthesis was performed
using 0.5 μg of DNase I-treated total RNA and 50 units
of AffinityScript reverse transcriptase according to the
manufacturer’s instructions (Stratagene, La Jolla, USA).
TaqMan PCR assays were performed in 384-well optical
plates on a LightCycler (Roche, Mannheim, Germany)
using Absolute QPCR ROX Mix (Abgene, Hamburg,
Germany) according to the manufacturer’s instructions.
The thermal cycling conditions were 95°C for 15 min
followed by 50 cycles at 95°C for 15 s and at 60°C for
1 min. Oligonucleotide primers and probes for human
GAPDH (GADPH forward: 5′-TGGGCTACACTGAG-
CACCAG-3′; GAPDH reverse: 5′-CAGCGTCAAAGG
TGGAGGAG-3′, GAPDH probe: 5′-FAM- TCTCCTC
TGACTTCAACAGCGACACCC-TAMRA-3′) were de-
signed using Primer Express (Applied Biosystems, Foster
City, USA) according to company guidelines. Oligo-
nucleotide primers and TaqMan probe for human BMP-
2 (Cat. Nr. Hs00154192) were purchased from Applied
Biosystems (Foster City, CA, USA). Assays were per-
formed in triplicate. Data were analyzed using the rela-
tive standard curve method, with each sample being
normalized to the housekeeping gene GAPDH.Determining systemic spread of the viral vector
Samples from the spleen, liver, and lung from all animals
in the Ad.GFP group were cut into 10-μm cryo-sections
and examined using fluorescence microscopy.
Figure 2 Quantification of transduction efficacy (RT-PCR). To test the transduction efficiency in vivo, Ad.BMP was injected into the quadriceps
muscle of two animals. Quantitative real-time RT-PCR was performed comparing the animals from the BMP group 3 days after transduction (B1, B2) to
untreated animals (N1, N2). To exclude systemic effects, the contralateral quadriceps of the treated animals was analyzed (K). Furthermore, we sacrificed
one animal after muscle flap perfusion (L). Both flaps (B1, B2) showed increased BMP-2 levels compared to the contralateral quadriceps (K) or the flap
of control animals (N1, N2).
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Prior to x-ray imaging, animals were anesthetized by
intramuscular administration of ketamine (10 mg per
100 g of body weight) and xylazine (0.25 mg per 100 g
of body weight). Animals were then positioned prone
with the left hind limb externally rotated. An x-ray
image was obtained between the third and thirteenth
day after surgery and on the day of euthanasia (14 weeks
postoperatively) using an OEC Mini 6600 C-arm x-ray-unit
(GE OEC Medical Systems GmbH 90530 Wendelstein)
(Figure 3A). Radiological density was determined by gray-
scale analysis using GIMP (GIMP, GNU General Public
License) image software [21]. The region of interest used in
the radiographic evaluation was defined as the area between
the second screw (proximally) and third screw (distally),
containing the whole cortex-to-cortex thickness of the
femur.
Histological study
Euthanasia was performed by CO2 asphyxiation after the
animals have been put under general anesthesia using
isoflurane (Forene® Abbott, Switzerland) at a flow rate of
1.5 l/min. After euthanasia, the left femur was removed
and placed in 4% formaldehyde for 24 h. For histomor-
phometric analysis, samples were embedded into
methyl-methacrylate-based hard plastic, without prior
demineralization of the bone using the Technovit 9100
kit (Heraeus Kulzer GmbH & Co.) and cut into 8-μm
sections. Von Kossa standard staining was used for all sec-
tions. Images were obtained (Zeiss Axiocam, Axiovert)
and analyzed using GIMP image software. Three sectionsshowing the greatest cortex-to-cortex thickness were eval-
uated. A region of interest was defined as a trapezoid area
with a length of 8,000 μm containing the defect in its cen-
ter. The parallel sides of this trapezoid were perpendicular
to the axis of the femur shaft and stretch between the
cortical bone of the proximal and distal bone fragment
(Figure 4A). The defect area was marked manually
and then compared to the total area of the region of
interest.
Statistical analysis
All data are presented as mean ± standard error of the




When determining the efficacy of transduction in
human mesenchymal stem cells (Figure 5A) and the
Cal-72 human osteosarcoma cell line (data not shown),
we observed an overwhelming (10- to 24-fold) increase
of BMP-2 in cell culture supernatants in transfected
cells compared to controls. In the MSC group, BMP-2
expression increased after the multiplicity of infection
(MOI) was doubled from 500 to 1,000 PFU/cell. Trans-
duction with Ad.GFP was confirmed by UV light micro-
scopic analysis (Figure 5B). Next, we analyzed the
kinetics of BMP-2 expression over time in a culture of
Sprague-Dawley rat myocytes (Figure 5C). A peak of
BMP-2 expression was seen on the fifth day after trans-
duction when using an MOI of 1,000. BMP-2 expression
Figure 3 Radiographic evaluation of bone formation. Animals were positioned prone with the left hind limb externally rotated for x-ray imaging.
X-ray images were obtained between the third and thirteenth day after surgery (A) and on the day of euthanasia (14 weeks postoperatively (B)).
Here, we present images from an animal of the Ad.BMP-2 group. The images were analyzed assessing radiological density by gray-scale analysis.
The region of interest used was defined as the area between the second screw and third screw (distally). An increase of high-density tissue,
corresponding to mineralized bone between the first and last x-ray was seen in all three groups (C). The increase was highest in the
Ad.BMP-2 group.
Lampert et al. Journal of Orthopaedic Surgery and Research  (2015) 10:55 Page 5 of 10demonstrated a stable plateau after the fifth day with
roughly identical values on the sixth an seventh day
post-transduction in both MOI 500 and MOI 1,000
cultures.
In vivo
To test the transduction efficiency in vivo, the Ad.BMP
was injected into the quadriceps muscle of two animals
as described above. Furthermore, we sacrificed one ani-
mal after muscle flap perfusion (executed as described in
surgical procedure). Quantitative real-time RT-PCR was
performed comparing the animals from the BMP group
3 days after transduction to untreated animals (Figure 2).
Furthermore, 1 ml containing 6 × 109 PFUs of Ad.GFP
was injected directly into the quadriceps muscle of one
animal as described above and showed GPF fluorescencewhen examined under UV light 3 days after transduc-
tion. As shown in Figure 6, we compared Ad.BMP-2 ex-
pression in the transfected flap on postoperative day 3 to
a sample from the contralateral quadriceps. Both flaps
showed increased BMP-2 levels compared to the contra-
lateral quadriceps or the flap of control animals. This
finding was consistent with our PCR findings (Figure 2),
which demonstrated the presence of human BMP-2
mRNA only in transfected flaps and not in the contralat-
eral quadriceps.
Radiographic analysis
An increase of high-density tissue, corresponding to
mineralized bone between the first and last x-ray,
was seen in all three groups. The increase was high-
est in the Ad.BMP-2 group showing an average of
Figure 4 Histomorphometric analysis of bone formation. For histomorphologic analysis of the mineralized area, Von Kossa stainings of samples of
the left femur were performed. Histomorphometric analysis of the mineralized area was performed within a region of interest, defined as a trapezoid
area with a length of 8,000 μm containing the defect in its center. The parallel sides of this trapezoid were perpendicular to the axis of the femur shaft
and stretch between the cortical bone of the proximal and distal bone fragment. The defect area was marked manually and then compared to the
total area of the region of interest ((A) 25×). Although nonunions were seen in the majority of animals, pronounced inter-individual differences within
the groups were detected regarding bone formation. However, in one case (Ad.BMP-2 group), a complete union was achieved. A statistical comparison
of the three groups showed little difference regarding the area of mineralized bone compared to the entire region of interest (B).
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42% and 37% in the GFP and control group, respect-
ively (Figure 3B).Histological evaluation
Although nonunions were seen in the majority of
the animals, pronounced inter-individual differences
within the groups were detected regarding bone
formation. A comparison between the three groups
showed little difference regarding the area of mineral-
ized bone compared to the entire region of interest
(Figure 4B). One case of mineralized bony union was
seen in group 1.Systemic spread of the viral vector (i.e., systemic
contamination)
Samples from the spleen, liver, and lung from all animals
in the Ad.GFP group were cut into 10-μm cryo-sections
and microscopically examined under UV light. Fluores-
cence was not observed in any of the sections.
Perioperative mortality
In the course of experiments, we lost five animals during
the operation in the 24-h period after the operation. Four
animals were excluded from the study and underwent
euthanasia after a dislocation of the osteosynthesis, two
due to wound dehiscence and one due to an ischemia of
the operated limb.
Figure 5 In vitro quantification of transduction efficacy. When determining the efficacy of transduction in human mesenchymal stem cells, we
observed an overwhelming (10- to 24-fold) increase of BMP-2 in cell culture supernatants in transfected cells compared to controls. BMP-2
expression increased after the multiplicity of infection (MOI) was doubled from 500 to 1,000 PFU/cell (A). In vivo microscopy of cell cultures
5 days after transduction with Ad.GFP in native ((B) 100×) and UV light ((C) 100×) highlights a successful transduction of human mesenchymal
stem cells. A peak in BMP-2 production on the fifth day after transduction was observed when using a MOI of 1,000 PFU/cell and a plateau after
the fifth day when MOI 500 was used (D).
Lampert et al. Journal of Orthopaedic Surgery and Research  (2015) 10:55 Page 7 of 10Discussion
Gene therapy is an innovative approach for treatment of
large bone defects. Previous studies demonstrated that
the adenoviral vector is particularly well equipped for
utilization in this regard [9-11]. Its favorable characteris-
tics include easy handling and ability to transduce target
tissue effectively. Furthermore, being replication deficient,
it does have a favorable safety profile. In order to decrease
technical complexity, yet continuing to minimize systemic
toxicity and immune response, we modified the concept
introduced by Michaels et al. by using the quadriceps
femoris muscle as a pedicled flap [14,15]. The current
model was chosen, as it resembles the clinical setting, inwhich muscle flaps are used to cover bone defects. The
concept of being able to use a muscle flap not only as soft
tissue coverage but also as a biologic pump that secretes
growth factors stimulating bone regeneration is intriguing.
While a quadriceps femoris free flap has been previously
described [22], we employed its modification as a pedicled
flap, thus, reducing technical complexity, ischemia time,
and overall risk of flap failure. In none of the animals in
group 1 did we detect an increase of BMP-2 expression in
tissues other than the transduced muscle flap. PCR
showed human BMP-2 mRNA in the transduced flap and
absence thereof in the contralateral quadriceps. Samples
from the spleen, liver, lung, and contralateral quadriceps
Figure 6 BMP-2 expression in tissue samples. BMP-2 expression in the transfected flap on postoperative day 3 was compared to a sample from
the contralateral quadriceps. Both flaps showed increased BMP-2 levels compared to the contralateral quadriceps and the flap of control animals.
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did not display any fluorescence, thus confirming indir-
ectly the lack of undesired systemic transduction.
In the present study, we were able to prove the con-
cept that delivery of BMP-2 via a genetically altered
muscle flap is possible without any measurable systemic
contamination. Unfortunately, a significant difference
between the groups with respect to ossification of the
critical-size defects could not be observed. An explan-
ation for this observation is the small sample size with
resultant limited power in the present study. We
achieved an overwhelming increase of BMP-2 expression
in human and rat cell types in vitro, which remained
stable on a high level in the first week after transduction.
The time kinetics of BMP-2 expression paralleled re-
ports of transgene expression being highest between the
5th and 14th day post-transduction [15]. The fact that
even in untreated cell culture supernatants and tissue
samples, the BMP-2 ELISA kit detected BMP-2 levels
higher than the minimum detectable concentration
suggests some cross-reactivity with rodent proteins. An
additional effect could be the induction of endogenous
BMP-2 expression as a result of bone injury, i.e., creation
of the critical-size femoral defect. This phenomenon has
already been shown for a myriad of growth factors includ-
ing PDGF, FGF, IGF, TGF-β, and VEGF [23-27].
In vivo BMP-2 expression was comparatively lower.
Human BMP-2 mRNA was however detected in the
muscle flaps of all Ad.BMP-2 transduced animals, thus,
proving that transduction was successful.
Follow-up x-ray images revealed that the Ad.BMP-2
group showed the most pronounced improvement in the
radiographical score for high mineralization. Due to the
small sample size and considerable inter-individual differ-
ences, however, statistical significance was not achieved.
The same applies for the histomorphometric data of theBMP-2 group. In conclusion, we were able to demonstrate
that continuous local expression of BMP-2 is possible by
means of muscle transduction. Shortcomings of topical
BMP-2 application, such as associated cost and necessity
for repeated applications secondary to the short half-life
of the protein, can, thus, be addressed successfully. Most
notably, this approach does not result in systemic contam-
ination with viral particles. Clinical application would be
particularly attractive as the need for harvesting autolo-
gous bone for reconstruction of composite defects could
be reduced or even averted. While this development may
not seem to be in reach at present, further development
of this model employing larger groups and later larger
animal model would provide important clinical data
regarding applicability in a clinical setting.
Limitations of the study include the small sample size.
The perioperative loss of 12 animals was likely caused
by the relatively long, complex, and invasive surgical
procedure consisting of microsurgical flap dissection,
osteosynthesis, and creation of the critical-size defect as
well as the incubation period of 1 h. The loss of animals
was evenly spread in all three groups.
Compared to other BMP-2 application models such as
direct recombinant BMP injections in the fracture site
or the use of biodegradable BMP carrier [28], the use of
an adenovirus as a vehicle of gene delivery has the disad-
vantage of a possible immune response which can lead
to a shorter duration of BMP-2 expression [29]. The re-
sults of the present study correspond to data published
by Willett et al. showing the reduced osteogenic poten-
tial of BMP-2 in vivo after a composite muscle-bone
injury compared to osseous injury alone, making further
investigation in this topic desirable [30]. Additional stud-
ies need to be carried out with larger sample size to ad-
dress limitation of the present study. These experiments
then need to be followed by large animal studies to
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above, a larger animal model would also be appropriate
to reduce the observed high dropout rate, since the
grade of invasiveness and duration of the procedure are
substantial in a small rodent model. Further modifica-
tions could include a transient immunosuppression
shortly before and after surgery as proposed by Okubo
[31] which may improve the osteogenetic potential of
the present model.
Conclusions
Gene therapy is a promising option for the treatment
of critical-size bony defects. We explored the effects of
adenovirus-mediated, self-sustained BMP-2 production
by a transduced pedicled quadriceps muscle flap in a
critical-size femoral defect in a rat model. Our aim was
to achieve high local BMP-2 expression while simultan-
eously minimizing the risks of systemic contamination
and initiation of an adverse immune response. While
statistical significance was not observed with respect to
enhanced bone formation, we were able to demonstrate
effective transduction and increased local BMP-2 expres-
sion by transduced flaps, both without evidence of sys-
temic viral contamination.
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